Literature DB >> 9712273

Development of rifapentine: the way ahead.

D A Mitchison1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9712273

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN： 1027-3719            Impact factor:   2.373


× No keyword cloud information.
  13 in total

1.  Recent Developments in Epidemiology, Treatment, and Diagnosis of Tuberculosis.

Authors: 
Journal:  Curr Infect Dis Rep       Date:  1999-04       Impact factor: 3.725

Review 2.  Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials.

Authors:  W J Burman; K Gallicano; C Peloquin
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

3.  A rifapentine-containing inhaled triple antibiotic formulation for rapid treatment of tubercular infection.

Authors:  John Gar Yan Chan; Anneliese S Tyne; Angel Pang; Hak-Kim Chan; Paul M Young; Warwick J Britton; Colin C Duke; Daniela Traini
Journal:  Pharm Res       Date:  2013-11-16       Impact factor: 4.200

4.  Weekly moxifloxacin and rifapentine is more active than the denver regimen in murine tuberculosis.

Authors:  Ian M Rosenthal; Kathy Williams; Sandeep Tyagi; Andrew A Vernon; Charles A Peloquin; William R Bishai; Jacques H Grosset; Eric L Nuermberger
Journal:  Am J Respir Crit Care Med       Date:  2005-09-01       Impact factor: 21.405

Review 5.  The chemotherapy of tuberculosis: past, present and future.

Authors:  D Mitchison; G Davies
Journal:  Int J Tuberc Lung Dis       Date:  2012-06       Impact factor: 2.373

Review 6.  Therapeutic drug monitoring in the treatment of tuberculosis.

Authors:  Charles A Peloquin
Journal:  Drugs       Date:  2002       Impact factor: 9.546

7.  Population pharmacokinetics of rifampicin, pyrazinamide and isoniazid in children with tuberculosis: in silico evaluation of currently recommended doses.

Authors:  Simbarashe P Zvada; Paolo Denti; Peter R Donald; H Simon Schaaf; Stephanie Thee; James A Seddon; Heiner I Seifart; Peter J Smith; Helen M McIlleron; Ulrika S H Simonsson
Journal:  J Antimicrob Chemother       Date:  2014-01-31       Impact factor: 5.790

8.  Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers.

Authors:  Simbarashe P Zvada; Jan-Stefan Van Der Walt; Peter J Smith; P Bernard Fourie; Giorgio Roscigno; Denis Mitchison; Ulrika S H Simonsson; Helen M McIlleron
Journal:  Antimicrob Agents Chemother       Date:  2010-06-01       Impact factor: 5.191

9.  Assessment of the Efficacy of New Anti-Tuberculosis Drugs.

Authors:  Denis A Mitchison; Geraint R Davies
Journal:  Open Infect Dis J       Date:  2008-12

10.  Bactericidal and sterilizing activities of several orally administered combined regimens against Mycobacterium ulcerans in mice.

Authors:  Baohong Ji; Aurélie Chauffour; Jérome Robert; Vincent Jarlier
Journal:  Antimicrob Agents Chemother       Date:  2008-04-07       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.